UA106506C2 - Інсулінвмісний фармацевтичний препарат для перорального застосування - Google Patents

Інсулінвмісний фармацевтичний препарат для перорального застосування

Info

Publication number
UA106506C2
UA106506C2 UAA201202346A UAA201202346A UA106506C2 UA 106506 C2 UA106506 C2 UA 106506C2 UA A201202346 A UAA201202346 A UA A201202346A UA A201202346 A UAA201202346 A UA A201202346A UA 106506 C2 UA106506 C2 UA 106506C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical preparation
insulin
oral administration
containing pharmaceutical
preparation intended
Prior art date
Application number
UAA201202346A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Др. Зольтан СИЛЬВАШШИ
Original Assignee
Цера-Мед Кфт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цера-Мед Кфт. filed Critical Цера-Мед Кфт.
Publication of UA106506C2 publication Critical patent/UA106506C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UAA201202346A 2009-08-03 2010-08-02 Інсулінвмісний фармацевтичний препарат для перорального застосування UA106506C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
UA106506C2 true UA106506C2 (uk) 2014-09-10

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202346A UA106506C2 (uk) 2009-08-03 2010-08-02 Інсулінвмісний фармацевтичний препарат для перорального застосування

Country Status (15)

Country Link
US (1) US20120129769A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461820A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013501043A (cg-RX-API-DMAC7.html)
KR (1) KR20120088660A (cg-RX-API-DMAC7.html)
CN (1) CN102791282A (cg-RX-API-DMAC7.html)
AU (1) AU2010280418B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002413A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769620A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0900482A2 (cg-RX-API-DMAC7.html)
IL (1) IL217856A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012001461A (cg-RX-API-DMAC7.html)
RU (1) RU2012109006A (cg-RX-API-DMAC7.html)
UA (1) UA106506C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011015984A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201519B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003824A1 (en) * 2011-06-29 2013-01-03 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3645736B1 (en) * 2017-06-28 2022-06-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for determining the risk to develop type 1 diabetes
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
DE68909135T2 (de) 1988-07-21 1994-04-07 Hoffmann La Roche Insulinzubereitung.
WO1993010767A1 (de) 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Perorale applikationsform für peptidarzneistoffe, insbesondere insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
NZ500075A (en) 1997-04-02 2001-03-30 Purdue Research Foundation Method for the oral delivery of a protein encapsulated within a hydrogel matrix
AU1574900A (en) 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
KR20060015472A (ko) 2003-03-04 2006-02-17 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 약물전달 시스템 및 세포 치료법
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
JP5222727B2 (ja) * 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
JP2011504871A (ja) * 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー/エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment

Also Published As

Publication number Publication date
MX2012001461A (es) 2012-05-22
BR112012002413A2 (pt) 2016-03-01
US20120129769A1 (en) 2012-05-24
CA2769620A1 (en) 2011-02-10
WO2011015984A1 (en) 2011-02-10
AU2010280418B2 (en) 2015-04-09
AU2010280418A1 (en) 2012-03-22
JP2013501043A (ja) 2013-01-10
HUP0900482A2 (en) 2011-03-28
EP2461820A1 (en) 2012-06-13
ZA201201519B (en) 2013-05-29
RU2012109006A (ru) 2013-09-10
KR20120088660A (ko) 2012-08-08
IL217856A0 (en) 2012-03-29
CN102791282A (zh) 2012-11-21
HU0900482D0 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PH12016500040A1 (en) Pcsk9 vaccine
MY167234A (en) Novel glucagon analogues
MX336412B (es) Nuevos analogos de glucagon.
NZ602541A (en) Long - acting formulations of insulins
NZ703153A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX2013011175A (es) Analogos de glucagon novedosos.
WO2011080102A3 (en) Glp-1 analogues and derivatives
PH12013500406A1 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
NZ600477A (en) Insulin analogues with chlorinated amino acids
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2012007159A3 (en) Novel gastro-retentive dosage forms
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
GB2501219A (en) Orally bioavailable peptide drug compositions and methods thereof
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
MX2015000016A (es) Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.
MY190257A (en) Optimised subcutaneous therapeutic agents
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
UA106506C2 (uk) Інсулінвмісний фармацевтичний препарат для перорального застосування
WO2011065867A3 (en) Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv